Personalized DBS Targeting for Treating Depression

Clinical Application of Personalized DBS Target Optimization for Treating Depression

NCT06784388•Second Affiliated Hospital, School of Medicine, Zhejiang University

Summary

The goal of this clinical trial is to optimize the target brain areas for deep brain stimulation (DBS) for depression based on personalized brain imaging and stereo-electroencephalography（SEEG), to administer long-term DBS treatment in the target brain areas, to assess the effectiveness and safety of DBS for refractory depression and to validate the method of personalized optimization of DBS targets. The main questions it aims to answer are: 1. Where is the optimal DBS target brain region for each patient? 2. What are the optimal DBS parameters for each patient ? 3. What are the neural biomarkers of depression symptoms for each patient? 4. Are the optimized DBS strategies effective in treating refractory depression?

Detailed Description

This clinical study is a prospective clinical trial focused on the personalized optimization methods and applications of DBS targets for depression. The study is divided into 4 phases and in each phase and participants will complete different tasks: 1. The preoperative assessment phase:Lasting 7 days, participants will be required to complete preoperative symptom assessments, brain imaging, and task-state functional magnetic resonance imaging(fMRI) assessment. 2. The SEEG assessment phase: Lasting 14 days, participants will be implanted SEEG electrodes and complete a series of SEEG assessments. 3. The DBS treatment phase: Lasting 421 days, participants will be implanted a DBS device and treated with the DBS. During this period, participants will be required to complete the appropriate depressive symptom assessment tasks, as well as follow-up visits every 2 weeks. 4. The efficacy observation phase after DBS shutdown: Lasting 2 months, if the participant has a good outcome at the DBS for depression phase, the electrical stimulation will be shut down for 2 months to observe the maintenance of the efficacy of the treatment, during which time, if the symptoms rebound, the DBS treatment will be restarted until the completion of the study at the end of the 2-month period. During this time participants will be required to complete the appropriate depressive symptom assessment tasks, and follow-up visits every 2 weeks.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. A psychiatrist-confirmed diagnosis of major depressive disorder in accordance with the Diagnostic And Statistical Manual Of Mental Disorders.5th Ed (DSM-V);
•2. A psychiatric examination by two trained psychiatrists and a diagnosis consistent with the DSM-V;
•3. A history of depression of at least 12 months duration in depressed patients (including MECT) who have failed to respond to a full dose and course of treatment with 2 or more antidepressants of different mechanisms;
•4. A 17-item score on the HAMD scale ⩾ 20 at initial screening;
•5. A score of ≤ 50 on the Gross Assessment of Functioning (GAF) scale;
•6. The patient himself/herself or legal guardian was able to fully understand the therapy and agreed to enroll after signing an informed consent form.

Exclusion Criteria

•1. Persons with severe or unstable cardiac, hepatic, renal, endocrine, hematologic, and other medical disorders and co-morbidities with psychotic symptoms, including personality disorders diagnosed by history, questioning, and clinical examination;
•2. Persons with psychiatric disorders other than depression (except generalized anxiety);
•3. Persons with a history of substance abuse within 12 months; persons with a previous history of epilepsy, and persons with febrile convulsions in childhood;
•4. Patients with a history of suicide attempts within the past 6 months or more than 2 suicide attempts within the past 2 years;
•5. Women who are breastfeeding, pregnant, and patients who are pregnant or intend to become pregnant during the clinical study;
•6. Contraindications to DBS surgery and MRI;
•7. Years of education less than or equal to 9 years;
•8. Patients who are involuntarily hospitalized.

Locations (1)

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Key Dates

Start Date

January 5, 2025

Primary Completion Date

December 30, 2027

Completion Date

December 30, 2028

Last Updated

January 20, 2025

Enrollment

ESTIMATED participants

Conditions

Treatment-resistant Depression (TRD)

Interventions

Deep Brain Stimulation(DBS)

DEVICE

Esketamine

DRUG

Contacts

Junming Zhu, Ph.D.

CONTACT

+86 13968055768 dr.zhujunming@zju.edu.cn

Auditory MMN EEG in TRD in Response to Ketamine

NCT05464264

Treatment-resistant Depression (TRD)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions